This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montine, T. J. Articles by Swift, L. L. Search for Related Content PubMed PubMed Citation Articles by Montine, T. J. Articles by Swift, L. L.

American Journal of Pathology, Vol 151, 1571-1575, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Central nervous system lipoproteins in Alzheimer's disease

TJ Montine, KS Montine and LL Swift
Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. tom.montine@mcmail.vanderbilt.edu

Alzheimer's disease (AD) is the most common form of dementia in the United States and has been associated with APOE genotype. Apolipoprotein (apo) E along with apoAI serve as the major apolipoproteins in the central nervous system; however, we are unaware of any study addressing lipoprotein metabolism in AD. We tested the hypothesis that lipoprotein metabolism is altered in patients with AD by isolating and characterizing ventricular fluid (VF) lipoproteins obtained during a rapid autopsy protocol from patients with AD and age- matched nondemented control patients. Our results demonstrated abnormalities in the protein and lipid constituents of VF lipoproteins from AD patients. Apolipoprotein concentration was reduced by half in AD patients relative to controls; however, there was no selective reduction in apoE or apoAI. In addition, cholesteryl ester fatty acids, but not phospholipid fatty acids, from AD patients demonstrated a significant reduction in some polyunsaturated fatty acids (18:2 and 22:6) and an enrichment in 18:0. None of these changes were directly related to APOE genotype. Our data indicate that VF lipoprotein composition is altered, at least terminally, in AD patients, and that these changes are not associated with APOE. These findings suggest that altered VF lipoprotein metabolism may be a component of AD pathogenesis.

This article has been cited by other articles:

				F.-S. Shie, M. D. Neely, I. Maezawa, H. Wu, S. J. Olson, G. Jurgens, K. S. Montine, and T. J. Montine Oxidized Low-Density Lipoprotein Is Present in Astrocytes Surrounding Cerebral Infarcts and Stimulates Astrocyte Interleukin-6 Secretion Am. J. Pathol., April 1, 2004; 164(4): 1173 - 1181. [Abstract] [Full Text] [PDF]

				S. Koch, N. Donarski, K. Goetze, M. Kreckel, H.-J. Stuerenburg, C. Buhmann, and U. Beisiegel Characterization of four lipoprotein classes in human cerebrospinal fluid J. Lipid Res., July 1, 2001; 42(7): 1143 - 1151. [Abstract] [Full Text] [PDF]

				E. E. Reich, W. R. Markesbery, L. J. Roberts II, L. L. Swift, J. D. Morrow, and T. J. Montine Brain Regional Quantification of F-Ring and D-/E-Ring Isoprostanes and Neuroprostanes in Alzheimer's Disease Am. J. Pathol., January 1, 2001; 158(1): 293 - 297. [Abstract] [Full Text] [PDF]

				K. S. Montine, C. N. Bassett, J. J. Ou, W. R. Markesbery, L. L. Swift, and T. J. Montine Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins J. Lipid Res., December 1, 1998; 39(12): 2443 - 2451. [Abstract] [Full Text]

				L. J. Roberts II, T. J. Montine, W. R. Markesbery, A. R. Tapper, P. Hardy, S. Chemtob, W. D. Dettbarn, and J. D. Morrow Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid J. Biol. Chem., May 29, 1998; 273(22): 13605 - 13612. [Abstract] [Full Text] [PDF]